Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s00395-017-0649-7.

Title:
MicroRNA-143 promotes cardiac ischemia-mediated mitochondrial impairment by the inhibition of protein kinase Cepsilon | Basic Research in Cardiology
Description:
The cardioprotection of protein kinase Cepsilon (PKCε) against myocardial infarction (MI) mediated by its anti-apoptotic property and underlying mechanism of targeted regulation by microRNA (miRNA) are not established. MI-induced injury, PKCε expression, and targeted regulation of miRNA-143 (miR-143) to PKCε have been evaluated using animal MI and cellular hypoxic models conjugated with series of state-of-art molecular techniques. The results demonstrated that PKCε significantly downregulated along with increased infarcted area and apoptotic and necrotic damage in MI model, and the targeted relationship and potential binding profile were established between miR-143 and PKCε. Both in vivo and in vitro ischemic tests showed that miR-143 induced apoptosis and necrosis, which was reversed by antagomiR-143 or AMO-143. The upregulation of miR-143 by transfection of miR-143 in vitro also induced cell loss, and this effect of miR-143 was completely reversed by co-transfection of miR-143 with AMO-143. The identically deleterious action of miR-143 on mitochondrial membrane potential and ATP synthesis was also observed in both animal MI and cellular hypoxic models, as well as miR-143 overexpressed models and converted by either antagomiR or AMO. Importantly, overexpression of miR-143 downregulated PKCε in all tested models and this downregulation was reversed in the presence of antagomiR or AMO. The direct targeted regulation of miR-143 on PKCε was confirmed by luciferase reporter and miRNA-masking tests. In conclusion, MI-mediated upregulation of miR-143 inhibits PKCε expression and consequently interference with the cardioprotection of PKCε to mitochondrial, and leads to mitochondrial membrane potential dissipation and myocardial death eventually.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {šŸ“š}

  • Education
  • Health & Fitness
  • Telecommunications

Content Management System {šŸ“}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {šŸ“ˆ}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {šŸ’ø}

We're unsure if the website is profiting.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {šŸ”}

pubmed, article, google, scholar, cas, wang, central, cell, zhang, res, injury, microrna, mitochondrial, liu, apoptosis, heart, kinase, myocardial, cardiac, protein, ischemiareperfusion, protects, targeting, pkcε, death, basic, chen, yang, circ, zhao, research, cepsilon, zhou, infarction, ischemic, sun, pkcepsilon, cardiol, mol, inhibition, hong, expression, necrosis, inhibits, dois, cells, physiol, liang, models, cardiomyocytes,

Topics {āœ’ļø}

regulating cystathionine-gamma-lyase expression month download article/chapter cardiac ischemia/reperfusion injury myocardial ischemia/reperfusion injury /r-mediated myocardial injury nf-kappab pathway chemically modified microrna-143-3p myocardial ischaemia/reperfusion injury simulated ischaemia–reperfusion injury exerts tumor-suppressing functions f-fdg pet/ct yuhong zhouĀ &Ā rong zhang state-province key laboratories article basic research myocardial infarction post-transplantation microrna-143 promotes apoptosis permeability transition pore full article pdf myocardial ischemia–reperfusion mitochondrial permeability transition ischemia–reperfusion injury ischemia/reperfusion injury hypoxia-induced apoptosis competing financial interests mir-143 targets ctgf cardiac cell fate smooth muscle cells ischemia/reperfusion ipc protein kinase cepsilon mediates adverse remodelling cardiac ischemic injury hypoxic preconditioning promotes microrna-143 inhibits growth article hong targeting reperfusion injury acute myocardial infarction mitochondrial membrane potential privacy choices/manage cookies related subjects apoptosis-related micrornas microrna-92a protects microrna-125b protects cellular hypoxic models targeting protein kinase heartbeat regulates cardiogenesis microrna expression profile suppressing cell apoptosis mir-143 induced apoptosis de ferranti sd mi-induced injury

Questions {ā“}

  • Duquesnes N, Lezoualc’h F, Crozatier B (2011) PKC-delta and PKC-epsilon: foes of the same family or strangers?

Schema {šŸ—ŗļø}

WebPage:
      mainEntity:
         headline:MicroRNA-143 promotes cardiac ischemia-mediated mitochondrial impairment by the inhibition of protein kinase Cepsilon
         description:The cardioprotection of protein kinase Cepsilon (PKCε) against myocardial infarction (MI) mediated by its anti-apoptotic property and underlying mechanism of targeted regulation by microRNA (miRNA) are not established. MI-induced injury, PKCε expression, and targeted regulation of miRNA-143 (miR-143) to PKCε have been evaluated using animal MI and cellular hypoxic models conjugated with series of state-of-art molecular techniques. The results demonstrated that PKCε significantly downregulated along with increased infarcted area and apoptotic and necrotic damage in MI model, and the targeted relationship and potential binding profile were established between miR-143 and PKCε. Both in vivo and in vitro ischemic tests showed that miR-143 induced apoptosis and necrosis, which was reversed by antagomiR-143 or AMO-143. The upregulation of miR-143 by transfection of miR-143 in vitro also induced cell loss, and this effect of miR-143 was completely reversed by co-transfection of miR-143 with AMO-143. The identically deleterious action of miR-143 on mitochondrial membrane potential and ATP synthesis was also observed in both animal MI and cellular hypoxic models, as well as miR-143 overexpressed models and converted by either antagomiR or AMO. Importantly, overexpression of miR-143 downregulated PKCε in all tested models and this downregulation was reversed in the presence of antagomiR or AMO. The direct targeted regulation of miR-143 on PKCε was confirmed by luciferase reporter and miRNA-masking tests. In conclusion, MI-mediated upregulation of miR-143 inhibits PKCε expression and consequently interference with the cardioprotection of PKCε to mitochondrial, and leads to mitochondrial membrane potential dissipation and myocardial death eventually.
         datePublished:2017-09-08T00:00:00Z
         dateModified:2017-09-08T00:00:00Z
         pageStart:1
         pageEnd:16
         sameAs:https://doi.org/10.1007/s00395-017-0649-7
         keywords:
            MicroRNA-143
            Myocardial infarction
            PKCε
            Mitochondria
            Apoptosis
            Necrosis
            Cardiology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00395-017-0649-7/MediaObjects/395_2017_649_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00395-017-0649-7/MediaObjects/395_2017_649_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00395-017-0649-7/MediaObjects/395_2017_649_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00395-017-0649-7/MediaObjects/395_2017_649_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00395-017-0649-7/MediaObjects/395_2017_649_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00395-017-0649-7/MediaObjects/395_2017_649_Fig6_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00395-017-0649-7/MediaObjects/395_2017_649_Fig7_HTML.gif
         isPartOf:
            name:Basic Research in Cardiology
            issn:
               1435-1803
               0300-8428
            volumeNumber:112
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Hong Hong
               affiliation:
                     name:Harbin Medical University
                     address:
                        name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ting Tao
               affiliation:
                     name:Harbin Medical University
                     address:
                        name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Si Chen
               affiliation:
                     name:Harbin Medical University
                     address:
                        name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Chaoqi Liang
               affiliation:
                     name:Harbin Medical University
                     address:
                        name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yue Qiu
               affiliation:
                     name:Harbin Medical University
                     address:
                        name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yuhong Zhou
               affiliation:
                     name:Harbin Medical University
                     address:
                        name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rong Zhang
               url:http://orcid.org/0000-0003-0006-3303
               affiliation:
                     name:Harbin Medical University
                     address:
                        name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:MicroRNA-143 promotes cardiac ischemia-mediated mitochondrial impairment by the inhibition of protein kinase Cepsilon
      description:The cardioprotection of protein kinase Cepsilon (PKCε) against myocardial infarction (MI) mediated by its anti-apoptotic property and underlying mechanism of targeted regulation by microRNA (miRNA) are not established. MI-induced injury, PKCε expression, and targeted regulation of miRNA-143 (miR-143) to PKCε have been evaluated using animal MI and cellular hypoxic models conjugated with series of state-of-art molecular techniques. The results demonstrated that PKCε significantly downregulated along with increased infarcted area and apoptotic and necrotic damage in MI model, and the targeted relationship and potential binding profile were established between miR-143 and PKCε. Both in vivo and in vitro ischemic tests showed that miR-143 induced apoptosis and necrosis, which was reversed by antagomiR-143 or AMO-143. The upregulation of miR-143 by transfection of miR-143 in vitro also induced cell loss, and this effect of miR-143 was completely reversed by co-transfection of miR-143 with AMO-143. The identically deleterious action of miR-143 on mitochondrial membrane potential and ATP synthesis was also observed in both animal MI and cellular hypoxic models, as well as miR-143 overexpressed models and converted by either antagomiR or AMO. Importantly, overexpression of miR-143 downregulated PKCε in all tested models and this downregulation was reversed in the presence of antagomiR or AMO. The direct targeted regulation of miR-143 on PKCε was confirmed by luciferase reporter and miRNA-masking tests. In conclusion, MI-mediated upregulation of miR-143 inhibits PKCε expression and consequently interference with the cardioprotection of PKCε to mitochondrial, and leads to mitochondrial membrane potential dissipation and myocardial death eventually.
      datePublished:2017-09-08T00:00:00Z
      dateModified:2017-09-08T00:00:00Z
      pageStart:1
      pageEnd:16
      sameAs:https://doi.org/10.1007/s00395-017-0649-7
      keywords:
         MicroRNA-143
         Myocardial infarction
         PKCε
         Mitochondria
         Apoptosis
         Necrosis
         Cardiology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00395-017-0649-7/MediaObjects/395_2017_649_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00395-017-0649-7/MediaObjects/395_2017_649_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00395-017-0649-7/MediaObjects/395_2017_649_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00395-017-0649-7/MediaObjects/395_2017_649_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00395-017-0649-7/MediaObjects/395_2017_649_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00395-017-0649-7/MediaObjects/395_2017_649_Fig6_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00395-017-0649-7/MediaObjects/395_2017_649_Fig7_HTML.gif
      isPartOf:
         name:Basic Research in Cardiology
         issn:
            1435-1803
            0300-8428
         volumeNumber:112
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Hong Hong
            affiliation:
                  name:Harbin Medical University
                  address:
                     name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ting Tao
            affiliation:
                  name:Harbin Medical University
                  address:
                     name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Si Chen
            affiliation:
                  name:Harbin Medical University
                  address:
                     name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Chaoqi Liang
            affiliation:
                  name:Harbin Medical University
                  address:
                     name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yue Qiu
            affiliation:
                  name:Harbin Medical University
                  address:
                     name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yuhong Zhou
            affiliation:
                  name:Harbin Medical University
                  address:
                     name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rong Zhang
            url:http://orcid.org/0000-0003-0006-3303
            affiliation:
                  name:Harbin Medical University
                  address:
                     name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Basic Research in Cardiology
      issn:
         1435-1803
         0300-8428
      volumeNumber:112
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Harbin Medical University
      address:
         name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
         type:PostalAddress
      name:Harbin Medical University
      address:
         name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
         type:PostalAddress
      name:Harbin Medical University
      address:
         name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
         type:PostalAddress
      name:Harbin Medical University
      address:
         name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
         type:PostalAddress
      name:Harbin Medical University
      address:
         name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
         type:PostalAddress
      name:Harbin Medical University
      address:
         name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
         type:PostalAddress
      name:Harbin Medical University
      address:
         name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Hong Hong
      affiliation:
            name:Harbin Medical University
            address:
               name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
               type:PostalAddress
            type:Organization
      name:Ting Tao
      affiliation:
            name:Harbin Medical University
            address:
               name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
               type:PostalAddress
            type:Organization
      name:Si Chen
      affiliation:
            name:Harbin Medical University
            address:
               name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
               type:PostalAddress
            type:Organization
      name:Chaoqi Liang
      affiliation:
            name:Harbin Medical University
            address:
               name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
               type:PostalAddress
            type:Organization
      name:Yue Qiu
      affiliation:
            name:Harbin Medical University
            address:
               name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
               type:PostalAddress
            type:Organization
      name:Yuhong Zhou
      affiliation:
            name:Harbin Medical University
            address:
               name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
               type:PostalAddress
            type:Organization
      name:Rong Zhang
      url:http://orcid.org/0000-0003-0006-3303
      affiliation:
            name:Harbin Medical University
            address:
               name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
      name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
      name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
      name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
      name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
      name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
      name:Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {šŸ”—}(332)

Analytics and Tracking {šŸ“Š}

  • Google Tag Manager

Libraries {šŸ“š}

  • Clipboard.js
  • Prism.js

CDN Services {šŸ“¦}

  • Crossref

4.14s.